Vilobelimab

FDA

• The FDA issued an Emergency Use and Authorization (EUA) permitting the use of vilobelimab for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults (>18 years of age) when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).